- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01972477
DLBS1449 in Diabetic Patients With Low HDL
3. august 2016 opdateret af: Dexa Medica Group
The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo
This is a parallel, 3-arm, randomized, prospective, placebo-controlled, and double-blind clinical study for eight weeks of therapy to investigate the clinical efficacy of DLBS1449 in elevating high density lipoprotein (HDL) cholesterol in diabetic patients.
The hypothesis of interest for the study is: the administration of DLBS1449 will elevate HDL-cholesterol level from baseline to the end of study significantly higher than the elevation resulted by placebo.
In addition, the administration of DLBS1449 at the dose of 150 mg daily will provide a significantly better response than that of the lower dose (DLBS1449 75 mg daily).
Studieoversigt
Status
Trukket tilbage
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
There will be three groups of treatment by dosage regimen in this study.
Eligible subjects will be randomized to receive any of the following regimens: 1) DLBS1449 at a dose of 1 x 75 mg daily, or 2) DLBS1449 at a dose of 1 x 150 mg (two capsules of DLBS1449 75 mg) daily; or 3) placebo, once daily.
Study medication should be administered once daily, in the evening with meal, for eight weeks.
Clinical and laboratory examinations to evaluate investigational drug's efficacy and safety will be performed at baseline and at interval of four weeks over 8-week course of therapy.
Undersøgelsestype
Interventionel
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
East Java
-
Surabaya, East Java, Indonesien
- Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital; Pusat Diagnostik Terpadu Building 7th Floor
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Male or female 21 - 70 years.
- Have been diagnosed diabetes mellitus and being treated with lifestyle intervention for at least 1 month prior to screening, with or without antidiabetic agents.
- HDL-cholesterol level of < 35 mg/dL.
- Triglycerides level of < 200 mg/dL.
- Adequate liver and renal function.
- Statin and/or fenofibrate therapy should have been being regularly taken for >=3 months at stable dose (ONLY for subjects currently under statin and/or fenofibrate therapy).
- Able to take oral medication.
Exclusion Criteria:
- Pregnant or breast-feeding women or willing to be pregnant.
- Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg).
- Any other disease state, including chronic/acute systemic infections, uncontrolled illnesses or other chronic diseases, which judged by the investigator, could interfere with trial participation or trial evaluation.
- Concurrent treatment with systemic corticosteroids or herbal (alternative) medicines.
- Known allergic or hypersensitive to drugs contain similar active substance with the study medication.
- Participation in any other clinical studies within 30 days prior to screening.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: DLBS1449, 1x75 mg
DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
|
Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily.
DLBS1449 will be given every day for 8 weeks.
Andre navne:
|
Eksperimentel: DLBS1449, 1x150 mg
DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
|
Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily.
DLBS1449 will be given every day for 8 weeks.
Andre navne:
|
Placebo komparator: Placebo
Placebo once daily, taken every day along the study period
|
Placebo will be given every day for 8 weeks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percent change in HDL-cholesterol level
Tidsramme: 8 weeks
|
8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percent change in HDL-cholesterol level
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Percent change in LDL-cholesterol level
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Percent change in sd LDL-cholesterol level
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Percent change in triglycerides level
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Percent change in total cholesterol level
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Change in Apo-A1
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Change in Apo-B
Tidsramme: 4 and 8 weeks
|
4 and 8 weeks
|
|
Response rate
Tidsramme: 8 weeks
|
Response rate is defined as percentage of subjects with HDL-cholesterol >= 40 mg/dL after 8 weeks of treatment.
|
8 weeks
|
Change in A1c level
Tidsramme: 8 weeks
|
8 weeks
|
|
Vital signs
Tidsramme: 4 and 8 weeks
|
Vital signs measurements include: blood pressure, heart rate, and respiratory rate.
|
4 and 8 weeks
|
Routine hematology
Tidsramme: 4 and 8 weeks
|
Routine hematology measurements include: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count.
|
4 and 8 weeks
|
Liver function
Tidsramme: 4 and 8 weeks
|
Liver function measurements include: serum ALT, serum AST, gamma-GT, and alkaline phosphatase.
|
4 and 8 weeks
|
Renal function
Tidsramme: 4 and 8 weeks
|
Renal function measurement includes: serum creatinine.
|
4 and 8 weeks
|
Electrocardiography (ECG)
Tidsramme: 8 weeks
|
The interpretation of ECG result will be recorded.
Any worsened changes from baseline condition will be counted as adverse events.
|
8 weeks
|
Adverse event
Tidsramme: 1-8 weeks
|
Adverse event will be observed and recorded during the study period.
|
1-8 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Askandar Tjokroprawiro, Prof, SpPD, K-EMD, FINASIM, MD, Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2016
Primær færdiggørelse (Forventet)
1. oktober 2017
Studieafslutning (Forventet)
1. januar 2018
Datoer for studieregistrering
Først indsendt
24. oktober 2013
Først indsendt, der opfyldte QC-kriterier
24. oktober 2013
Først opslået (Skøn)
30. oktober 2013
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
4. august 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. august 2016
Sidst verificeret
1. august 2016
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- DLBS1449-0111
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetespatienter
-
The University of Texas at ArlingtonAgency for Healthcare Research and Quality (AHRQ)RekrutteringPatientengagement | Patient Empowerment | Patient aktiveringForenede Stater
-
Columbia AsiaAfsluttetPatient Compliance | Læge-patient forholdIndien
-
University of AarhusUkendtPatientengagement | Patient Empowerment | Patient Compliance
-
Peking Union Medical College HospitalAfsluttetPatient efter hjerteklapkirurgi | Patient med langvarig mekanisk ventilationKina
-
University of British ColumbiaAfsluttetMeddelelse | Tilfredshed | Læge-patient forhold | Sygeplejerske-patient relationerCanada
-
University of California, San DiegoPatient-Centered Outcomes Research Institute; University of Massachusetts... og andre samarbejdspartnereAfsluttetPatientengagement | Læge-patient forhold | Lægens rolle | Patient aktiveringForenede Stater
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityAfsluttet
-
University of Dublin, Trinity CollegeDublin Dental University HospitalRekrutteringOverholdelse, patientIrland
-
Fondazione Policlinico Universitario Agostino Gemelli...Ikke rekrutterer endnuHjertekirurgisk patient
-
AltaMed Health Services CorporationNational Institute on Aging (NIA); University of Southern CaliforniaRekrutteringPatient GenindlæggelseForenede Stater